Kim Blickenstaff - Tandem Diabetes Insider

TNDM -- USA Stock  

USD 36.27  0.14  0.39%

  CEO
Mr. Kim D. Blickenstaff is the President, Chief Executive Officer, and Director of Tandem Diabetes Care, Inc. Prior to joining our company, he served as Chairman and Chief Executive Officer of Biosite Incorporated, or Biosite, a provider of medical diagnostic products, from 1988 until its acquisition by Inverness Medical Innovations, Inc. in June 2007. Mr. Blickenstaff currently serves as Chairman of Medivation, Inc., and is a member of its audit committee. Mr. Blickenstaff previously served as a director of DexCom, Inc., a provider of glucose monitoring systems, from June 2001 to September 2007
Age: 64  CEO Since 2007  MBA    
858-366-6900  http://www.tandemdiabetes.com
Blickenstaff was formerly a certified public accountant and has more than 20 years of experience overseeing the preparation of financial statements. He received a B.A. in Political Science from Loyola University, Chicago, and an M.B.A. from the Graduate School of Business, Loyola University, Chicago. We believe Mr. Blickenstaff brings to our board of directors valuable perspective and experience as our President and Chief Executive Officer, extensive experience at the board level of various healthcare companies, as well as leadership skills, industry experience and knowledge that qualify him to serve as one of our directors.

Kim Blickenstaff Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (25.45) % which means that it has lost $25.45 on every $100 spent on asset. This is way below average.
The company currently holds 77.1 M in liabilities with Debt to Equity (D/E) ratio of 296.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Tandem Diabetes Care has Current Ratio of 2.96 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 5 records

CEO Since

Richard CarreonImpediMed Limited
2015
Tim RooneyAvita Medical Limited
2017
Adam KelliherAvita Medical Limited
2015
Ravinder MlaitCannabix Technologies
2014
Todd NewtonApollo Endosurgery
2014

Entity Summary

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California. Tandem Diabetes operates under Medical Devices classification in USA and is traded on NASDAQ General Markets. It employs 574 people.Tandem Diabetes Care (TNDM) is traded on NASDAQ General Markets in USA. It is located in 11045 Roselle Street and employs 574 people.

Tandem Diabetes Care Leadership Team

Brian Hansen, Chief Commercial Officer, Executive Vice President
Fred Cohen, Independent Director
Susan Morrison, Chief Admin. Officer
Lori Gildea, Vice President - Sales
Howard Greene, Independent Director
Christopher Twomey, Independent Director
Henry Anhalt, Independent Director
Edward Cahill, Independent Director
Lonnie Smith, Chairman of the Board
John Cajigas, CFO and Executive VP
Dick Allen, Chairman of the Board
David Berger, General Counsel
Jesse Treu, Independent Director
Richard Valencia, Independent Director
Douglas Roeder, Independent Director
Leigh Vosseller, Senior Vice President - Finance
John Sheridan, COO and Executive VP
Kim Blickenstaff, CEO and President and Director
Robert Anacone, Chief Commercial Officer and Executive VP

Stock Performance Indicators

Current Sentiment - TNDM

Tandem Diabetes Care Investor Sentiment

Most of Macroaxis users are at this time bullish on Tandem Diabetes Care. What is your outlook on investing in Tandem Diabetes Care? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip
Currently Active Assets on Macroaxis
ALLY   
Purchased over 90 shares of
a day ago
Traded for 26.13
RS   
Purchased over 90 shares of
a day ago
Traded for 80.82
IP   
Purchased over 90 shares of
a day ago
Traded for 42.67
LEN   
Purchased over 90 shares of
a day ago
Traded for 42.9
STLD   
Purchased over 90 shares of
a day ago
Traded for 42.39
Also please take a look at World Market Map. Please also try Piotroski F Score module to get piotroski f score based on binary analysis strategy of nine different fundamentals.
Search macroaxis.com